Tylenol, Theraflu, NyQuil, and DayQuil
Allegations: Falsely marketing that phenylephrine products treat nasal congestion
Wilson et al. v. Johnson & Johnson Consumer, Inc. et al.
23-cv-21276, D.N.J.
(Oct. 2023)
Children’s Dimetapp, DayQuil, Mucinex, Mucinex Children’s, and Sudafed
Falsely marketing that phenylephrine products treat nasal congestion when phenylephrine is not an effective decongestant when taken orally
Pending
Allegations: Falsely marketing that phenylephrine products treat nasal congestion
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Falsely marketing that medicines are decongestants
Allegations: Falsely marketing the products treat nasal congestion
Allegations: Falsely marketing that phenylephrine products treat congestion and other cold and flu symptoms
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Misleadingly marketing drink mixes using the phrase “Natural fruit flavor” and images of raspberries when they contain artificial flavoring ingredients
Allegations: Misleadingly marketing products as if they treat symptoms of coughs and colds
Allegations: False natural claims
Allegations: False natural claims
In November 2020, a class-action lawsuit was filed against GSK Consumer Health for allegedly falsely advertising Benefiber prebiotic powders as “100% Natural” when, according to plaintiffs, the powders contain wheat…
In August 2020, a class-action lawsuit was filed against GlaxoSmithKline Consumer Healthcare for allegedly misleadingly advertising Benefiber Prebiotic Supplement as “100% Natural” when, according to plaintiffs, the company uses a…
How negative feelings surrounding menstruation have influenced period product marketing.
Class-action lawsuits target preservative-free claims.
A closer look at what we’ll be monitoring in the new year.
Some class-action settlements that left consumers behind.
What consumers should know about software tethering.